Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Gemcitabine + LY2603618|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Gemcitabine||Gemzar||Difluorodeoxycytidine Hydrochlorothiazide|LY-188011||Chemotherapy - Antimetabolite 11||Gemzar (gemcitabine) is converted in cells to difluorodeoxycytidine di- and triphosphate (dFdCDP, dFdCTP), which act to inhibit ribonucleoside reductase and as a deoxynucleotide analog respectively, resulting in DNA strand termination and apoptosis (NCI Drug Dictionary).|
|LY2603618||CHK1 Inhibitor 14||LY2603618 is a small molecule that inhibits CHK1, which may lead to disruption of DNA synthesis, early mitosis, and apoptosis, and may increase tumor cell sensitivity to chemotherapeutics (PMID: 24114124).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||pancreatic cancer||no benefit||Gemcitabine + LY2603618||Phase II||Actionable||In a Phase II trial, treatment with the combination of LY2603618 and Gemzar (gemcitabine) did not result in improved overall survival, progression-free survival, duration of response, or clinical benefit compared to Gemzar (gemcitabine) alone in patients with unresectable pancreatic cancer (PMID: 28202004).||28202004|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|